Investigating microparticles in patients with obstructive sleep apnea
Microparticles as a Biomarker of Incident Cardiovascular Risk in Patients With Obstructive Sleep Apnea
This study is testing how higher levels of certain tiny particles in the blood might affect heart health in people who have both obstructive sleep apnea and existing heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Locations | 1 site (Angers) |
| Trial ID | NCT03438149 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the impact of increased levels of leukocyte-derived microparticles (MPs) on cardiovascular outcomes in patients diagnosed with obstructive sleep apnea (OSA) who also have prevalent cardiovascular diseases. It focuses on understanding how these microparticles, which are known to be elevated in OSA, may contribute to endothelial dysfunction and other cardiovascular risks. The study will involve assessing patients with coronary artery disease or cerebrovascular disease who are also diagnosed with moderate-to-severe OSA, to determine the relationship between MP levels and cardiovascular prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with moderate-to-severe obstructive sleep apnea and prevalent cardiovascular diseases such as coronary artery disease or cerebrovascular disease.
Not a fit: Patients who are pregnant or have previously treated obstructive sleep apnea may not receive benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the cardiovascular risks associated with obstructive sleep apnea, potentially leading to improved management strategies for affected patients.
How similar studies have performed: While there is growing evidence regarding the role of microparticles in cardiovascular diseases, this specific approach focusing on OSA and its cardiovascular implications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of coronary artery disease or cerebrovascular disease * diagnosis of moderate-to-severe OSA Exclusion Criteria: * pregnancy * previously treated OSA
Where this trial is running
Angers
- Laboratoire du Sommeil, Département de Pneumologie, CHU d'Angers — Angers, France (Recruiting)
Study contacts
- Study coordinator: Wojciech Trzepizur, MD
- Email: wotrzepizur@chu-angers.fr
- Phone: 0680575272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.